Key points are not available for this paper at this time.
Our results suggest that both primary tumors and metastases of PDAC have highly fibrotic stroma. Thus, stromal targeting agents have the potential to benefit PDAC patients, even those with metastatic disease.
Whatcott et al. (Thu,) studied this question.